DSIP
DSIP is an endogenous neuropeptide historically studied for roles in sleep regulation, stress adaptation, pain and neuroendocrine function. Findings across studies have been inconsistent and much of the work is old and of limited quality; there are no completed modern controlled efficacy trials and no regulatory approval. It remains a research compound.
Mechanism
In plain terms, DSIP was discovered as a blood-borne factor that seemed to encourage deep sleep, but exactly how it works remains uncertain. Technically, it is a small amphiphilic nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that can cross the blood-brain barrier and has been reported to influence neurotransmitter and neuroendocrine systems (including effects on corticotropin and other hormones) and circadian regulation. No single well-defined receptor has been established, and its physiological role is still debated.
Regulatory Status by Region
- United States (FDA)Not FDA-approved; an experimental peptide with no approved therapeutic use.
- Australia (TGA)Not on the ARTG; an unapproved experimental substance.
- European Union (EMA)No EMA marketing authorisation; not an approved medicine in the EU.
- WADANot listed by name on the Prohibited List; as a non-approved substance, athletes should verify current status with their anti-doping organisation.